Hikma's ANDA for Solriamfetol Hydrochloride Receives Approval Status
Hikma's ANDA218016 for Solriamfetol Hydrochloride has received an Approval Pending status from the FDA.
Therapeutic Area
Therapeutic area intelligence for Wakefulness Promoting Agent with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.